查看文章

Reports of long-term outcomes of therapies in Waldenström macroglobulinemia (WM) are particularly important given the protracted course of the disease. In a large phase 2 study in 72 patients, using contemporary criteria for diagnosis and initiation of therapy, 1, 2 primary therapy with dexamethasone, rituximab, and cyclophosphamide (DRC) was active with limited toxicity. 3 DRC is one of the most commonly used regimens for symptomatic WM and is evaluated, with or without bortezomib, in the randomized European Consortium for Waldenstr öm Macroglobulinemia (ECWM-1) study (NCT01788020). Herein we present outcomes after a minimum follow-up of 7 years (median 8, range 7 to 10 years), and this is one of the few studies in WM with long-term data. Patients were enrolled between November 2002 and April 2006. Inclusion required the presence of CD20 1 lymphoplasmacytoid lymphoma involving the …